Zydus Lifesciences is currently trading at Rs. 643.55, up by 15.90 points or 2.53% from its previous closing of Rs. 627.65 on the BSE.
The scrip opened at Rs. 626.95 and has touched a high and low of Rs. 644.20 and Rs. 626.05 respectively. So far 20030 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.
Last one week high and low of the scrip stood at Rs. 644.20 and Rs. 622.60 respectively. The current market cap of the company is Rs. 64943.02 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.56% and 7.47% respectively.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at the injectables manufacturing facility at Zydus Biotech Park located at Changodar, Ahmedabad from June 5 to 13, 2023. The inspection was a cGMP Inspection and had ended with NIL observations.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
